Novo Nordisk’s 48% Crash: Value Trap or Opportunity?

What happened

Novo Nordisk’s stock has fallen ~48% from its mid-2025 peak, wiping out over $150 billion in market cap, as the narrative shifted from GLP-1 dominance to a U.S. price war. The company’s early-2026 guidance warned of “unprecedented pricing pressure,” and it has responded with multi-month subscription discounts and a new oral Wegovy Pill, but these moves signal structurally lower net prices. Meanwhile, Eli Lilly’s Foundayo (orforglipron) launched in April 2026, intensifying competition in both injectable and oral GLP-1 classes. A one-time $4.2 billion 340B revenue recognition in Q1 2026 provides an earnings cushion, but the market remains focused on sustained price compression and share loss. The stock now trades at ~10x P/E and 8x EBITDA, with clear catalysts—Medicare Part D obesity coverage in mid-2026 and prescription stabilization—but also material downside risk from faster-than-expected net price erosion.

Implication

Investors should view NVO as a high-risk, high-reward play dependent on U.S. prescription trends stabilizing after the cash-pay reset and the Foundayo launch. The low valuation (10x P/E) provides a margin of safety if the price war doesn’t accelerate, but thesis breakers include continued weekly Rx declines, broader subscription discounting, or failure to recognize the 340B revenue. The next 6-9 months offer clear catalysts: the Medicare Part D obesity pilot, 1Q26 earnings with the 340B tailwind, and early Foundayo uptake data. If scripts stabilize and net prices hold, the stock could re-rate to the base case of $40; if not, the bear case of $30 becomes likely. Position sizing should reflect the binary outcome—this is not a core holding but a tactical bet on a turnaround narrative that has yet to prove itself. The key thesis delta is that Novo’s access investments may eventually stabilize volume, but the price paid is a durable step-down in U.S. net pricing, compressing long-term earnings power.

Thesis delta

The DeepValue report’s thesis is shifting from a defensive thesis based on manufacturing scale and patent protection to an offensive thesis that hinges on observable stabilization of U.S. GLP-1 prescription trends and net price declines. The launch of Lilly’s Foundayo and the expansion of Novo’s subscription program raise the probability that net price compression becomes structural rather than cyclical. The key question now is whether volume growth and the 340B tailwind can offset lower realizations, a scenario that will be tested over the next two quarters.